Press Releases Sanofi

Equities

SAN

FR0000120578

Pharmaceuticals

Real-time Euronext Paris Other stock markets 16:06:24 08/05/2026 BST			5-day change	1st Jan Change
72.83 ^EUR	-1.23%		-6.41%	-11.97%

01:52pm	A lot of noise, little impact?
09:20am	Berenberg Calls for More Acquisitions from Sanofi; Estimates Updated	MT

Press Releases

04-29	Annual General Meeting of April 29, 2026 - Belén Garijo appointed as Director and Chief Executive Officer of Sanofi	GL
04-27	Sanofi's Cenrifki recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses	AQ
04-24	Sanofi successfully prices 2.3 billion of bond issue	GL
04-24	Sanofi’s Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses	GL
04-23	Phase 3 EMN24 IsKia Study: Quadruplet Isa-KRd Regimen Significantly Improves MRD Negativity in Newly Diagnosed Multiple Myeloma \| DelveInsight's Perspective on Treatment Paradigm Shift	AQ
04-23	Q1 2026: double-digit sales and business EPS growth	GL
04-22	Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria	GL
04-22	Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children	GL
04-22	Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US	GL
04-18	ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study	GL
04-13	Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria	GL
04-08	Sanofi - Combined General Meeting of April 29, 2026 - Availability of Preparatory documents	GL
04-07	Sanofi : lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP	PU
04-07	Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP	GL
04-01	Sanofi's Rezurock approved in the EU to treat chronic graft-vs-host disease	AQ
03-31	Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease	GL
03-30	AAD, new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session	AQ
03-30	Sanofi's Sarclisa subcutaneous formulation administered via on-body injector recommended for EU approval by the CHMP to treat multiple myeloma	AQ
03-28	AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session	GL
03-27	Sanofi’s Sarclisa subcutaneous formulation administered via on-body injector recommended for EU approval by the CHMP to treat multiple myeloma	GL
03-24	Availability of the Q1 2026 aide-mémoire	GL
03-24	Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid	GL
03-18	Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease	GL
03-12	Sanofi: Informations relatives au nombre de droits de vote et d'actions - FEVRIER 2026	PU
03-08	Brazil’s EMS buys Medley	AQ